Trials / Completed
CompletedNCT05658484
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
A Multicenter, Postmarketing Study of Dimethyl Fumarate (Tecfidera; BG00012) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimethyl fumarate | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2023-06-09
- Primary completion
- 2025-03-27
- Completion
- 2025-04-12
- First posted
- 2022-12-20
- Last updated
- 2025-05-16
Locations
15 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05658484. Inclusion in this directory is not an endorsement.